BioAtla, Inc. filings document the regulatory record for a clinical-stage biotechnology company developing CAB antibody therapeutics for solid tumors. Recent Form 8-K disclosures cover financial results, investor presentation materials, cost-reduction actions, executive retention compensation, financing arrangements, license-related updates and risk-linked operating disclosures.
The filings also record capital-structure and governance matters, including shareholder votes on stock issuance and reverse split authority, Series A Junior Preferred Stock issuance and elimination, Nasdaq continued-listing proceedings, and a Delaware certificate of merger connected to a common-stock reclassification.
BioAtla, Inc. filed an amended annual report to add detailed Part III information on directors, executive compensation, ownership and governance that was originally planned to come from its proxy statement. The amendment does not change prior financial statements but reflects a 50-for-1 share consolidation effective April 6, 2026. As of April 27, 2026, BioAtla had 1,659,612 common shares outstanding. The filing outlines the board’s structure, committee memberships and independence, and describes compensation philosophy emphasizing pay-for-performance and equity incentives. For 2025, the CEO’s base salary was $734,820, other named executives received modest salary increases, and no annual cash bonuses were paid because corporate performance did not meet the 50% threshold under the bonus plan. In March 2025, the compensation committee granted time-vested RSUs to executives and maintained severance and change-in-control protections, stock ownership guidelines, an insider trading policy banning hedging and pledging, and a compensation clawback policy.
BioAtla, Inc. is implementing a reverse stock split through an internal merger structure. On April 2, 2026, the company filed a Certificate of Merger in Delaware for a merger between BioAtla and its wholly owned subsidiary, BA Merger Sub, Inc.
At the effective time of the merger on April 6, 2026 at 12:01 a.m. Eastern Time, BA Merger Sub will merge into BioAtla, with BioAtla continuing as the surviving corporation. Every fifty (50) shares of BioAtla common stock issued and outstanding or held as treasury stock will be converted into one (1) share of common stock of the surviving corporation.
The company’s Amended and Restated Certificate of Incorporation will remain in effect for the surviving corporation. The full Certificate of Merger is available as Exhibit 99.1, and BioAtla’s common stock will continue to trade on The Nasdaq Capital Market under the symbol BCAB.
BioAtla, Inc. is a clinical-stage biopharmaceutical company developing conditionally active biologics (CAB antibodies) for solid tumors, using pH-sensitive designs to concentrate activity in the acidic tumor microenvironment while sparing normal tissue.
The company’s lead programs include CAB bispecific BA3182 in a Phase 1 adenocarcinoma study, CAB-ADC ozuriftamab vedotin (BA3021) targeting ROR2 with plans for a Phase 3 trial in previously treated HPV-associated oropharyngeal cancer, and CAB-ADC mecbotamab vedotin (BA3011) targeting AXL, along with CAB anti-CTLA-4 evalstotug.
On March 2, 2026, the board began a formal process to explore strategic options, including asset sales, licensing, partnerships or other transactions, and implemented a workforce reduction and cost-containment measures. As part of capital preservation, BioAtla is re-evaluating the timing and scope of key clinical programs and the previously announced $40 million ozuriftamab SPV investment structure, even as it highlights a broad patent estate and multiple out-licensing and collaboration agreements.
BioAtla, Inc. is a clinical-stage biopharmaceutical company developing conditionally active biologics (CAB antibodies) for solid tumors, using pH-sensitive designs to concentrate activity in the acidic tumor microenvironment while sparing normal tissue.
The company’s lead programs include CAB bispecific BA3182 in a Phase 1 adenocarcinoma study, CAB-ADC ozuriftamab vedotin (BA3021) targeting ROR2 with plans for a Phase 3 trial in previously treated HPV-associated oropharyngeal cancer, and CAB-ADC mecbotamab vedotin (BA3011) targeting AXL, along with CAB anti-CTLA-4 evalstotug.
On March 2, 2026, the board began a formal process to explore strategic options, including asset sales, licensing, partnerships or other transactions, and implemented a workforce reduction and cost-containment measures. As part of capital preservation, BioAtla is re-evaluating the timing and scope of key clinical programs and the previously announced $40 million ozuriftamab SPV investment structure, even as it highlights a broad patent estate and multiple out-licensing and collaboration agreements.
BioAtla, Inc. reported a full-year 2025 net loss of $59.6 million and a fourth-quarter 2025 net loss of $9.8 million, reflecting lower collaboration revenue and high R&D spending. R&D expenses were $43.6 million in 2025, down from $63.1 million, while G&A expenses fell to $17.7 million from $21.8 million after workforce reductions.
Cash and cash equivalents declined to $7.1 million as of December 31, 2025, with total assets of $13.8 million and a stockholders’ deficit of $36.2 million, indicating financial strain. The company has fully converted its Pre-paid Advance Agreements into common stock and is using a Standby Equity Purchase Agreement to extend runway.
BioAtla’s board initiated a formal process to explore strategic options, including potential asset sales, licensing deals, partnerships, or other transactions, and implemented additional reductions in force and cost-containment measures. While continuing key programs such as the Phase 1 BA3182 study and advanced assets Ozuriftamab Vedotin, Mecbotamab Vedotin, and Evalstotug, the company warns that clinical development may be limited or delayed pending the outcome of this strategic review.
BioAtla, Inc. reported a full-year 2025 net loss of $59.6 million and a fourth-quarter 2025 net loss of $9.8 million, reflecting lower collaboration revenue and high R&D spending. R&D expenses were $43.6 million in 2025, down from $63.1 million, while G&A expenses fell to $17.7 million from $21.8 million after workforce reductions.
Cash and cash equivalents declined to $7.1 million as of December 31, 2025, with total assets of $13.8 million and a stockholders’ deficit of $36.2 million, indicating financial strain. The company has fully converted its Pre-paid Advance Agreements into common stock and is using a Standby Equity Purchase Agreement to extend runway.
BioAtla’s board initiated a formal process to explore strategic options, including potential asset sales, licensing deals, partnerships, or other transactions, and implemented additional reductions in force and cost-containment measures. While continuing key programs such as the Phase 1 BA3182 study and advanced assets Ozuriftamab Vedotin, Mecbotamab Vedotin, and Evalstotug, the company warns that clinical development may be limited or delayed pending the outcome of this strategic review.
BioAtla, Inc. reports that stockholders approved an internal merger with its wholly owned subsidiary BA Merger Sub, Inc., which will include a 1-for-50 consolidation of its common stock at the merger’s effective time. The company plans to complete the merger and share consolidation as soon as Nasdaq notice requirements are satisfied.
Separately, BioAtla’s board approved 2026 cash retention bonuses for key executives in place of a regular bonus plan or salary increases. The CFO and Chief Medical Officer can each earn milestone-based bonuses tied to financial and capital raising goals in May and August 2026, while the CEO’s bonus is a single milestone-based payment tied to August 2026 objectives.
BioAtla is registering 842,440 shares of common stock to be issued to YA II PN, Ltd. pursuant to its Standby Equity Purchase Agreement dated November 20, 2025. The shares are priced at approximately $0.179 per share for total proceeds of approximately $151,000, which the company intends to use for working capital and general corporate purposes. The company expects to issue the shares on or about March 20, 2026. This prospectus supplement also covers the resale of these shares by YA II PN, Ltd. to the public.
Common stock outstanding after the offering will be 82,846,317 shares. The resale and methods of sale are described in the referenced "Plan of Distribution."
BioAtla is offering 631,163 shares of common stock to YA II PN, Ltd. (Yorkville) at approximately $0.171 per share pursuant to a Standby Equity Purchase Agreement dated November 20, 2025. The total purchase price is approximately $108,000 and the company expects to issue the shares on or about March 13, 2026. This prospectus supplement also covers the resale of those shares by Yorkville to the public. Common stock outstanding after the issuance will be 81,801,593 shares. The company states it intends to use net proceeds for working capital and other general corporate purposes.
Sievers Eric reported acquisition or exercise transactions in this Form 4 filing.
BioAtla, Inc. reported that Chief Medical Officer Eric Sievers received a grant of 240,000 shares of Common Stock in the form of time-based restricted stock units (RSUs) at no purchase price.
The RSU vests as to 25% of the shares on March 10, 2027, then 6.25% on the last day of each May, August, November, and February, subject to his continued service through each vesting date. Following this award, Sievers directly holds 598,705 shares of Common Stock.
SHORT JAY M PHD reported acquisition or exercise transactions in this Form 4 filing.
BioAtla, Inc. CEO and director Jay M. Short received a grant of 430,000 shares of Common Stock in the form of a time-based restricted stock unit award. The award was granted at no cash cost and is structured to vest over several years.
According to the vesting schedule, 25% of the RSU is scheduled to vest on March 11, 2027, with an additional 6.25% vesting on the last day of each May, August, November and February thereafter, subject to his continued service. Following this grant, Dr. Short directly holds 2,659,603 shares of Common Stock.
The filing also lists indirect holdings in BioAtla shares held by his spouse, various 2020 irrevocable gift trusts, Capia IP, LLC and Himalaya Parent LLC. For Himalaya Parent LLC, he and his spouse act as managers and collectively make investment decisions, while each disclaims beneficial ownership except to the extent of any pecuniary interest.
Vasquez Christian reported acquisition or exercise transactions in this Form 4 filing.
BioAtla, Inc. Chief Financial Officer Christian Vasquez received a grant of 240,000 shares of Common Stock in the form of time-based restricted stock units. These units carry no purchase price and increase his direct holdings to 530,196 shares after the award.
The RSU grant vests over time: 25% of the shares vest on March 10, 2027, with an additional 6.25% vesting on the last day of each May, August, November, and February thereafter, as long as he remains in service through each vesting date.